Endometrial adenosquamous carcinoma
disease diseaseOn this page
Also known as adenosquamous carcinoma of the endometriumendometrial adenosquamous cancerendometrium adenosquamous carcinoma
Summary
Endometrial adenosquamous carcinoma (MONDO:0003556) is a cancer and 12 clinical trials. Top therapeutic interventions include cabozantinib, cisplatin, and filgrastim. A subtype of adenosquamous carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 12
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | endometrial adenosquamous carcinoma |
| Mondo ID | MONDO:0003556 |
| EFO | EFO:1001952 |
| DOID | DOID:5631 |
| NCIT | C114656 |
| UMLS | C3896969 |
| MedGen | 856563 |
| Anatomy (UBERON) | UBERON:0001295 |
| Is cancer (heuristic) | yes |
Also known as: adenosquamous carcinoma of the endometrium · endometrial adenosquamous cancer · endometrial adenosquamous carcinoma · endometrium adenosquamous carcinoma
Data availability: 8 cell lines.
Disease family
This is a subtype of adenosquamous carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › squamous cell neoplasm › squamous cell carcinoma › adenosquamous carcinoma › endometrial adenosquamous carcinoma
Related subtypes (14): adenosquamous breast carcinoma, esophageal adenosquamous carcinoma, thymic adenosquamous carcinoma, Bartholin gland adenosquamous carcinoma, adenosquamous prostate carcinoma, adenosquamous lung carcinoma, pancreatic adenosquamous carcinoma, gastric adenosquamous carcinoma, cervical adenosquamous carcinoma, colorectal adenosquamous carcinoma, gallbladder adenosquamous carcinoma, salivary gland adenosquamous carcinoma, liver adenosquamous carcinoma, skin adenosquamous carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 12.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 9 |
| PHASE1 | 2 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00006011 | PHASE3 | COMPLETED | Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer |
| NCT00977574 | PHASE2 | ACTIVE_NOT_RECRUITING | Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer |
| NCT00064025 | PHASE2 | COMPLETED | Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus |
| NCT00820898 | PHASE2 | COMPLETED | Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer |
| NCT01005329 | PHASE2 | COMPLETED | Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer |
| NCT01011933 | PHASE2 | COMPLETED | Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer |
| NCT01132820 | PHASE2 | COMPLETED | Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer |
| NCT01210222 | PHASE2 | COMPLETED | Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer |
| NCT01307631 | PHASE2 | COMPLETED | Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer |
| NCT01935934 | PHASE2 | COMPLETED | Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer |
| NCT00575952 | PHASE1 | COMPLETED | Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer |
| NCT02020707 | PHASE1 | COMPLETED | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CABOZANTINIB | 4 | 3 |
| CISPLATIN | 4 | 3 |
| FILGRASTIM | 4 | 1 |
| IXABEPILONE | 4 | 1 |
| MEDROXYPROGESTERONE ACETATE | 4 | 1 |
| PACLITAXEL | 4 | 1 |
| PEGFILGRASTIM | 4 | 1 |
| SELUMETINIB | 4 | 1 |
| TEMSIROLIMUS | 4 | 1 |
| CEDIRANIB MALEATE | 3 | 1 |
| TREBANANIB | 3 | 1 |
| CHEMBL48 | 0 | 1 |
| CHEMBL1390 | 0 | 1 |
| CHEMBL4559687 | 0 | 1 |
| CHEMBL4792931 | 0 | 1 |
| CHEMBL4463209 | 0 | 1 |